Pages that link to "Q35010607"
Jump to navigation
Jump to search
The following pages link to Alpha-fetoprotein triggers hepatoma cells escaping from immune surveillance through altering the expression of Fas/FasL and tumor necrosis factor related apoptosis-inducing ligand and its receptor of lymphocytes and liver cancer cells (Q35010607):
Displaying 23 items.
- Transformation of human liver L-O2 cells mediated by stable HBx transfection (Q33552832) (← links)
- GALNT14 genotype, α-fetoprotein and therapeutic side effects predict post-chemotherapy survival in patients with advanced hepatocellular carcinoma (Q33733830) (← links)
- Serum tumor markers for detection of hepatocellular carcinoma (Q34501851) (← links)
- Risk factors for residual tumor after resection of hepatocellular carcinoma (Q34831310) (← links)
- Transforming growth factor-beta signaling promotes hepatocarcinogenesis induced by p53 loss (Q35613285) (← links)
- Alpha fetoprotein antagonizes apoptosis induced by paclitaxel in hepatoma cells in vitro (Q36965059) (← links)
- Immunotherapy for liver tumors: present status and future prospects. (Q37144014) (← links)
- Icaritin inhibits the expression of alpha-fetoprotein in hepatitis B virus-infected hepatoma cell lines through post-transcriptional regulation (Q37696374) (← links)
- Hepatic resection after transarterial chemoembolization increases overall survival in large/multifocal hepatocellular carcinoma: a retrospective cohort study (Q37702238) (← links)
- Alpha-fetoprotein: a renaissance. (Q38114382) (← links)
- Activation of cellular immunity and marked inhibition of liver cancer in a mouse model following gene therapy and tumor expression of GM-SCF, IL-21, and Rae-1. (Q39042194) (← links)
- Differential effects of vitamin K1 on AFP and DCP levels in patients with unresectable HCC and in HCC cell lines. (Q39614993) (← links)
- Down-regulation of beta-centractin might be involved in dendritic cells dysfunction and subsequent hepatocellular carcinoma immune escape: a proteomic study (Q40109673) (← links)
- Changes of alpha-fetoprotein levels could predict recurrent hepatocellular carcinoma survival after trans-arterial chemoembolization (Q45385200) (← links)
- Lipiodolized transarterial chemoembolization in hepatocellular carcinoma patients after curative resection (Q45720793) (← links)
- Clinical significance of alpha-fetoprotein: involvement in proliferation, angiogenesis, and apoptosis of hepatocellular carcinoma (Q47720290) (← links)
- Effects of harmaline on cell growth of human liver cancer through the p53/p21 and Fas/FasL signaling pathways (Q50053686) (← links)
- Serum alpha-fetoprotein levels during and after interferon therapy and the development of hepatocellular carcinoma in patients with chronic hepatitis C. (Q50565830) (← links)
- Nonsecreted cytoplasmic alpha-fetoprotein: a newly discovered role in intracellular signaling and regulation. An update and commentary. (Q53432260) (← links)
- The role of ERCC1 and AFP gene polymorphism in hepatocellular carcinoma (Q64227697) (← links)
- Post-treatment alpha-fetoprotein response predicts prognosis of patients with hepatocellular carcinoma: A meta-analysis (Q92367636) (← links)
- Drug-eluting bead transarterial chemoembolization is efficient and well-tolerated in treating elderly Chinese hepatocellular carcinoma patients (Q92714352) (← links)
- AFP promotes HCC progression by suppressing the HuR-mediated Fas/FADD apoptotic pathway (Q100427917) (← links)